Use of botulinum toxin in the treatment of blepharospasm: A literature review
DOI:
https://doi.org/10.33448/rsd-v14i7.49237Keywords:
Botulinum Toxin, Blepharospasm, Treatment.Abstract
This study examines the use of botulinum toxin as an alternative treatment for blepharospasm, a condition characterized by involuntary muscle contractions around the eyes. The focus is on the efficacy and safety of this treatment in improving patients' quality of life. The article aims to review the scientific literature on the use of botulinum toxin for blepharospasm, understanding its effectiveness, mechanisms of action, and possible adverse effects. This is a bibliographic review based on the analysis of scientific studies published in recognized databases. Articles discussing botulinum toxin treatment, its clinical effects, and outcomes in patients diagnosed with blepharospasm were selected. Results and Discussion: The reviewed studies demonstrate that botulinum toxin is effective in treating blepharospasm, providing symptom relief for the majority of patients. Although some adverse effects such as eyelid ptosis and blurred vision may occur, adjustments in dosage and injection technique can mitigate these effects, leading to improved outcomes. Conclusion: The study concludes that botulinum toxin is a safe and effective option for the treatment of blepharospasm. However, individualized monitoring is necessary to tailor the intervention. Future studies should focus on improving application methods to further reduce side effects.
References
Ali, F. R. & Al-Niaimi, F. (2016). Justinus Kerner and sausage poisoning: the birth of botulinum toxin. International Journal of Dermatology. 55(11):1295-1296. doi: 10.1111/ijd.13364.
AAO. (2018). Chemodenervation for the treatment of facial dystonia: a report by the American Academy of Ophthalmology. Ophthalmology (AAO). 125(10), 1459-67. doi: 10.1016/j.ophtha.2018.03.013.
Amatya, M., Limbu, B., Sthapit, P. R., Gurung, H. B. & Saiju, R. (2021). Outcome of Injection Botulinum Toxin in Blepharospasm. Nepal J Ophthalmol. 13(25):40-49. doi: 10.3126/nepjoph.v13i1.30589. PMID: 33981096.
Anwar, M. S. & Zafar, H. (2013). Botulinum toxin in patients suffering from Benign Essential Blepharospasm (BEB). Pakistan Journal of Medical Sciences. 29(6), 1389-94.
Aquino, C. C., Felício, A. C., Castro, P. C. F., Oliveira, R. A., Silva, S. M. C. A., Borges, V. & Ferraz, H. B. (2012). Clinical features and treatment with botulinum toxin in blepharospasm: a 17-year experience. Arquivos de Neuro Psiquiatria. 70(9), 662–6.
Ayoub, N. (2025). Botulinum Toxin Therapy: A Comprehensive Review on Clinical and Pharmacological Insights. Journal of Clinical Medicine. 14(6). doi: 10.3390/jcm14062021. Cabral, S. R. (2021). Toxina botulínica e o seu uso clínico. UNIC-Campos.
Çakar, A., Samanci, B., Hanağasi, H. A. & Parman, Y. (2023). Clinical characteristics and treatment responses of patients with blepharospasm treated with botulinum toxin. Turkish Journal of Neurology. 29 (1), 27-33.
Chen, S. (2012). Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins. 4, 913-39.
Cillino, S., Raimondi, G., Guépratte, N., Damiani, S. et al. (2010). Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study. Eye. 24 (7), 1049-55.
Colorado-Ochoa, H. J. (2024). 12-year effectiveness and safety of botulinum toxin type A for the treatment of blepharospasm and hemifacial spasm. Revista Mexicana de Neurociencia. https://www.scielo.org.mx/pdf/rmn/v25n4/2604-6180-rmn-25-4-109.pdf.
Colosimo, C., Suppa, A., Fabbrini, G. et al. (2010). Craniocervical dystonia: clinical and pathophysiological features. European Journal of Neurology. 17(suplemento 10, 15-21.
Contento, R. J., Anderson, C. J., Hill, R. H., Carruth, B. P., Salloum, G. & Bersani, T. A. (2025). Exploratory prospective randomized controlled study to evaluate a modified botulinum toxin injection pattern for treatment of benign essential blepharospasm. Cureus, v. 17, n. 1, p. e76905. Doi: 10.7759/cureus.76905.
Costa, M. B. M. (2020). Efeito da suplementação de zinco e fitase no aumento da durabilidade do tratamento com toxina botulínica. 2020. Monografia (Graduação em Odontologia) – Centro Universitário Odontológico, CIODONTO.
Costa, P. G., Aoki, L., Saraiva, F. P. & Matayoshi, S. (2005). Toxina botulínica no tratamento de distonias faciais: avaliação da eficácia e da satisfação dos pacientes ao longo do tratamento. Arquivos Brasileiros de Oftalmologia. 68(4), 489-93. doi: 10.1590/S0004-27492005000400010.
Crossetti, M. G. M. (2012). Revisión integradora de la investigación en enfermería el rigor científico que se le exige. Maria Da Graça Oliveira Crossetti. Rev. Gaúcha Enferm.33(2):8-9.
Duarte, G. S., Rodrigues, F. B., Marques, R. E., Castelão, M., Ferreira, J., Sampaio, C., Moore A. P. & Costa, J. (2020). Botulinum toxin type A therapy for blepharospasm. Cochrane Database of Systematic Reviews. (Issue 11), Art. No.: CD004900. doi: 10.1002/14651858.CD004900.pub3.
Defazio, G., Jinnah, H. A., Berardelli, A., Perlmutter, J. S., Berkmen, G. K., Berman, B. D., Jankovic, J., Bäumer, T., Comella, C., Cotton, A. C., Ercoli, T., Ferrazzano, G., Fox, S., Kim, H. J., Moukheiber, E. S., Richardson, S. P., Weissbach, A., Wrigth, L. J. & Hallett, M. (2021). Critérios diagnósticos para blefaroespasmo: um estudo internacional multicêntrico. Parkinsonismo Relat Disord. 91:109-14. doi: 10.1016/j.parkreldis.2021.09.004. Epub 2021 8 de setembro. PMID: 34583301; PMCID: PMC9048224.
Escobar, S. O. et al. (2024). Is the duration and effectiveness of cosmetic effects from botulinum toxin decreasing? Results from a survey of 400 healthcare professionals. Journal of Dermatology & Cosmetology. 8(3), 54–6. https://medcraveonline.com/JDC/is-the-duration-and-effectiveness-of-cosmetic-effects-from-botulinum-toxin-decreasing-results-from-a-survey-of-400-healthcare-professionals.html.
Fang, X., Xie, M., Song, Z., Zhong, Z., Wang, Y. & Ou, Z. (2020). Long-term treatment of blepharospasm with botulinum toxin A: a service-based study over a 16-year follow-up in southern China. Neurological Sciences. 41, 2631–8.
Fernandez, H. H. et al. (2014). Observational study of incobotulinumtoxinA for cervical dystonia or blepharospasm (XCiDaBLE): interim results for the first 170 subjects with blepharospasm. Tremor and Other Hyperkinetic Movements. 4, 1-10. http://www.tremorjournal.org.
Fonfria, E., Maignel, J., Lezmi, S., Martin, V. & Splevins, A. (2018). The expanding therapeutic utility of botulinum neurotoxins. Toxins. 10(5), 208. doi: 10.3390/toxins10050208.
Gil, A. C. (2022). Métodos e técnicas de pesquisa social. (8ed). Atlas. Gill H. S. & Kraft S. P. (2010). Eficácia a longo prazo da toxina botulínica A para blefaroespasmo e espasmo hemifacial. Jornal Canadense de Ciências Neurológicas / Jornal Canadien des Sciences Neurologiques. 37(5):631-6. doi:10.1017/S0317167100010817.
Gonçalves, H. A. (2003). Manual de projetos de pesquisa científica. Avercamp. Gunes, A., Demirci, S., Koyuncuoglu, H. R., Tok, & Tok, O. (2015). Corneal and tear film changes after botulinum toxin-A in blepharospasm or hemifacial spasm. Cornea. 34(8), 906–10.
Gusev, V. V., Makarov, E. A. & Lvova, O. A. (2025). Sravnitel'nyi retrospektivnyi analiz effektivnosti preparatov botulinicheskogo toksina tipa A — gemagglyutinin kompleksa Relatoksa i Botoksa v lechenii patsientov s idiopaticheskim blefarospazmom [Comparative analysis of the effectiveness of Botulinum toxin type A - hemagglutinin preparations of the Relatox and Botox complex in the treatment of patients with primary idiopathic blepharospasm]. Zh Nevrol Psikhiatr Im S S Korsakova. 125(2):86-90. Russian. doi: 10.17116/jnevro202512502186. PMID: 40047837.
Ho, R. W., Fang, P. C., Chao, T. L., Chien, C. C. & Kuo, M. T. (2018). Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm. Scientific Reports. 8(1), 1–7.
Hu, J., Mu, Q., Ma, F., Wang, H., Chi, L. & Shi, M. (2024). Combination of pretarsal and preseptal botulinum toxin injections in the treatment of blepharospasm: a prospective nonrandomized clinical trial. American Journal of Ophthalmology. 270, 19–24. https://www.ajo.com/article/S0002-9394(24)00477-X/fulltext.
Jin, L. et al. (2013). O anticorpo IGF-1 prolonga o tempo de duração efetivo da toxina botulínica na diminuição da força muscular. International Journal of Molecular Sciences. 14(5), 9051-61. doi: 10.3390/ijms14059051.
Kattimani, V. et al. (2019). Botulinum toxin application in facial esthetics and recent treatment indications (2013-2018). J Int Soc Prev Community Dent. 9(2), 99-105.
Koshy, J. C. et al. (2012). Effect of dietary zinc and phytase supplementation on botulinum toxin treatments. Journal of Drugs in Dermatology. 11(4):507-12. https://pubmed.ncbi.nlm.nih.gov/22453589/.
Koirala, S. (2020). The role of Jankovic Spasm Grading, Orbicularis Oculi Muscle Function, and Functional Improvement Scale pre- and post-treatment in dosing botulinum toxin A in essential blepharospasm and Meige’s syndrome. Acta Scientific Ophthalmology. doi: 10.31080/ASOP.2020.03.0144.
Lacerda, V. R. L., Ferreira, P. O. A. & Silva, M. V. B. (2024). Fatores contribuintes no efeito prolongado da toxina botulínica. Research, Society and Development. https://rsdjournal.org/index.php/rsd/article/view/44675.
Lee, S., Park, S. 7 Lew, H. (2018). Long-term efficacy of botulinum neurotoxin-A treatment for essential blepharospasm. Korean Journal of Ophthalmology. 32(6), 480–5. https://synapse.koreamed.org/pdf/10.3341/kjo.2017.0030.
Li, X. H. et al. (2012). Efficacy of carbamazepine combined with botulinum toxin A in the treatment of blepharospasm and hemifacial spasm. Eye Science. 27 (3), 145–9. https://pubmed.ncbi.nlm.nih.gov/23225838/.
Lolekha, P., Choolam, A. & Kulkantrakorn, K. (2017). A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques. Neurological Sciences. 38, 2031-6. doi: 10.1007/s10072-017-3107-2.
Martinez-Ramirez, D., Giugni, J. C. & Gomez, C. et al. (2014). Comparable botulinum toxin outcomes between primary and secondary blepharospasm: a retrospective analysis. Tremor and Other Hyperkinetic Movements. 15(4), 286. doi: 10.7916/D8H41Q4X. eCollection 2014.
Mitsikostas, D. D., Dekundy, A., Hanschmann, A., Althaus, M., Scheschonka, A., Pagan, F. & Jankovic, J. (2021). Duração e início do efeito da toxina incobotulínica A para o tratamento de blefaroespasmo em indivíduos virgens de toxina botulínica. Curr Med Res Opin. 37(10):1761-1768. doi: 10.1080/03007995.2021.1965975. Epub 2021 24 de agosto. PMID: 34384301.
Minayo, M. C. S. (1994). O desafio do conhecimento: pesquisa qualitativa em saúde. (14 ed). Hucitec. Murugesan, S. & Bansal, R. (2024). Botulinum Toxin in Oculoplasty: An Overview. TNOA Journal of Ophthalmic Science and Research. 62(3): 283-288, doi: 10.4103/tjosr.tjosr_87_24.
Nicoletti, A. G. B. et al. (2010). Blefaroespasmo essencial: revisão da literatura. Arquivos Brasileiros de Oftalmologia. 73(5), 469-73. Oliveira, L. L. (2023). O uso da toxina botulínica tipo B como alternativa terapêutica. Trabalho de Conclusão de Curso (TCC) do curso de bacharelado em Biomedicina. Faminas. https://bibliotecadigital.faminas.edu.br/handle/10.31.16.45/382.
Oliveira, R. C. G. (2019). Complicações perioculares com toxina botulínica. Face Magazine.
Pachiappan, S., Gopalakrishnan, P. & Chandrasekar, S. (2025). Exploring the mechanisms and management strategies of blepharospasm. https://www.researchgate.net/publication/391251173_Exploring_the_Mechanisms_and_Management_Strategies_of_Blepharospasm.
Paik, J. S. et al. (2025). Tear film lipid layer thickness and blink dynamics in patients with blepharospasm. BMC Ophthalmology. https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-025-03852-z.
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D. et al. (2021). PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 372 (160): 1–36.
Polo, C. G., Sanz, M. F. R., Izquierdo, N. B. & Sanz, A. C. (2013). Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin. Neurología (English Edition). 28 (7), 415–20.
PRISMA. (2021). Transparent Reporting of Systematic Reviews and Meta-Analyses. https://www.prisma-statement.org/.
Ramirez-Castaneda, J. & Jankovic, J. (2014). Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon. 90, 344–8.
Reis, C. L., Luz, U. D., Silva, A. B. A., Fernandes, R. F. & Assis, B. I. (2020). Desvendando o uso da toxina botulínica na estética e em enfermidades. Revista Saúde em Foco, n.12. https://portal.unisepe.com.br/unifia/wp-content/uploads/sites/10001/2020/12/DESVENDANDO-O-USO-DA-TOXINA-BOTUL%C3%8DNICA-NA-EST%C3%89TICA-E-EM-ENFERMIDADES-413-%C3%A0-437.pdf.
Romero-Caballero, M. D. et al. (2023). Effects of the periocular botulinum toxin on the ocular surface and anterior chamber: a prospective study in patients with hemifacial spasm and blepharospasm. International Ophthalmology. 43(8):2731-2736. doi: 10.1007/s10792-023-02672-8. Epub 2023 Apr 26.
Sacramento, D. R. C. (2018). Comparação entre as técnicas pré-tarsal e pré-septal na aplicação de toxina botulínica em blefaroespasmo e espasmo hemifacial. Dissertação (Mestrado). Universidade Federal de Minas Gerais. http://hdl.handle.net/1843/BUOS-B3XMDM.
Santos, T. L. & Quaresma, M. P. (2018). Aplicações de toxina botulínica tipo A como um meio terapêutico em doenças distônicas. Revinter. 11(1), 84-99. doi: http://dx.doi.org/10.22280/revintervol11ed1.352.
Scott, A. B., Fahn. S. & Brin, M. F. (2023). Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 102(S1):e32374. doi: 10.1097/MD.0000000000032374. PMID: 37499080; PMCID: PMC10374181.
Siqueira, A. M. & et al. (2017). Benefícios e implicações da toxina botulínica em tratamento estético e terapêutico. Revista de Biomedicina. https://www.repositoriodigital.univag.com.br/index.php/biomedicina/article/view/514
Skopljak-Salkica, A., Gabric, I., Jagic, M. & Lipozenčić, J. (2024). Clinical study on the use of botulinum toxin for blepharospasm and hemifacial spasm. Medical Archives. 78(1), 56–61.
Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of business research, 104, 333-339.
Souza, O. A. & Cavalcanti, D. S. P. (2016). Toxina botulínica tipo A: aplicação e particularidades no tratamento da espasticidade, do estrabismo, do blefaroespasmo e de rugas faciais. Saúde & Ciência em Ação. 2(2). https://revistas.unifan.edu.br/index.php/RevistaICS/article/view/233.
Tater, P. & Pandey, S. (2018). Botulinum toxin in movement disorders. Neurology India. 66(Suppl 1):p S79-S89. doi: 10.4103/0028-3886.226441.
Thitiwichienlert, S., Sirikietsoong, P., Lolekha, P. & Sapthanakorn, W. (2024). Efficacy and complications of full dose versus half dose of botulinum toxin type A injection in benign essential blepharospasm. Journal of the Medical Association of Thailand, Bangkok. 107, 778–85. https://www.mdpi.com/2077-0383/14/6/2021.
Vijayakumar, D. & Jankovic, J. (2018). Medical treatment of blepharospasm. Expert Review of Ophthalmology. 13(4), 225–32. Vilela, T. R. P. et al. (2024). Blefaroespasmo essencial e espasmo hemifacial. Archives of Health. 5(3), 1-6. doi: 10.46919/archv5n3espec-663.
Vivancos-Matellano, F., Rodríguez-Sanz, A. et al. (2019). Efficacy and safety of long-term therapy with type A botulinum toxin in patients with blepharospasm. Neuro-Ophthalmology. 43(5), 287–92.
Wabbels, B. & Lieberz, R. (2025). Depressive symptoms and quality of life in patients with benign essential blepharospasm under long-term therapy with botulinum toxin. Acta Neurologica Belgica. 125(1):157-68. doi: 10.1007/s13760-024-02658-y. Epub 2024 Nov 1.
Wang, B.; Wei, X.; Qi, H.; Bao, X. F.; Hu, M.; Ma, J. (2025). Efficacy and safety of botulinum neurotoxin in the treatment of hemifacial spasms: a systematic review and meta-analysis. BMC Neurology, v. 24, 2024. https://link.springer.com/content/pdf/10.1186/s12883-024-03883-x.pdf.
Wenninger, F. C. & Wabbels, B. (2022). Frequency of Hemorrhagic Side Effects of Botulinum Neurotoxin Treatment in Patients with Blepharospasm and Hemifacial Spasm on Antithrombotic Therapy. Toxins. 14(11), 769. https://www.mdpi.com/2072-6651/14/11/769.
Xavier, E. C., Andrade, L. G. & Lobo, L. C. (2021). Toxina botulínica aplicada para fins terapêuticos. Revista Ibero-Americana de Saúde e Envelhecimento. Doi: https://doi.org/10.51891/rease.v7i9.2233.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Maria Eduarda Wanderley Mendonça, Emily Jeane Oliveira Pereira, Carolayne Araújo de Oliveira Freitas Gonçalves
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
